Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + CAPEOX neoadjuvant therapy for locally advanced rectal cancer
ChiCTR2400091748Phase 2Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib, capecitabine and oxaliplatin in rectal adenocarcinoma, sponsored by The Second Xiangya Hospital. Primary endpoint: Pathological complete response. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
fruquintinibcapecitabineoxaliplatin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400091748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091748.